Myriad Genetics Inc. (MYGN)

44.32
0.27 0.61
NASDAQ : Health Technology
Prev Close 44.59
Open 44.52
Day Low/High 43.89 / 44.97
52 Wk Low/High 27.23 / 50.44
Volume 1.12M
Avg Volume 724.20K
Exchange NASDAQ
Shares Outstanding 74.72M
Market Cap 3.32B
EPS 1.90
P/E Ratio 24.42
Div & Yield N.A. (N.A)

Latest News

The Law Offices Of Howard G. Smith Reminds Investors Of June 19th Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc. (MYGN)

The Law Offices Of Howard G. Smith Reminds Investors Of June 19th Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc. (MYGN)

Law Offices of Howard G. Smith reminds investors of the June 19, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Myriad Genetics, Inc.

Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors Of The Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc. Investors (MYGN)

Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors Of The Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc. Investors (MYGN)

National securities law firm Glancy Prongay & Murray LLP ("GPM") reminds investors of the  June 19, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Myriad Genetics, Inc.

FINAL DEADLINE NOTICE: Kaskela Law LLC Alerts Myriad Genetics, Inc. Investors Of Class Action Lawsuit And Important June 19, 2018 Deadline

FINAL DEADLINE NOTICE: Kaskela Law LLC Alerts Myriad Genetics, Inc. Investors Of Class Action Lawsuit And Important June 19, 2018 Deadline

Kaskela Law LLC announces that a class action lawsuit has been filed against Myriad Genetics, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADM, AFSI, CKX, EML, EVH, GDEN, MVC, MYGN, PANW, SO, SYKE, TARO Downgrades: IRCP, RMCF, UEIC, WYND Initiations: CALA, FG, MTNB Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Myriad Genetics, Inc. Of Class Action Lawsuit And Upcoming Deadline - MYGN

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Myriad Genetics, Inc. Of Class Action Lawsuit And Upcoming Deadline - MYGN

Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Myriad Genetics, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Myriad Genetics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Myriad Genetics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Myriad Genetics, Inc. Of Class Action Lawsuit And Upcoming Deadline - MYGN

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Myriad Genetics, Inc. Of Class Action Lawsuit And Upcoming Deadline - MYGN

Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc.

MYRIAD GENETICS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

MYRIAD GENETICS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc.

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of purchasers of Myriad Genetics, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Myriad Genetics, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Myriad Genetics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Myriad Genetics, Inc.

Myriad Genetics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches Of Fiduciary Duty By Officers And Directors

Myriad Genetics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, announces that a federal class action lawsuit has been filed against Myriad Genetics ("Myriad" or "Company") (NasdaqGS: MYGN) and...

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Myriad Genetics, Inc. (MYGN) And June 19 Lead Plaintiff Deadline

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Myriad Genetics, Inc. (MYGN) And June 19 Lead Plaintiff Deadline

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Myriad Genetics, Inc.

The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Myriad Genetics, Inc. Shareholders And A Lead Plaintiff Deadline Of June 19, 2018

The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Myriad Genetics, Inc. Shareholders And A Lead Plaintiff Deadline Of June 19, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Myriad Genetics, Inc.

MYGN EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Myriad Genetics, Inc. And A Lead Plaintiff Deadline Of June 19, 2018

MYGN EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Myriad Genetics, Inc. And A Lead Plaintiff Deadline Of June 19, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Myriad Genetics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 19, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Myriad Genetics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 19, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Myriad Genetics, Inc.

MYGN Crosses Above Average Analyst Target

In recent trading, shares of Myriad Genetics, Inc. have crossed above the average analyst 12-month target price of $33.36, changing hands for $33.55/share.

The Klein Law Firm Announces A Class Action Commenced On Behalf Of Myriad Genetics, Inc. Shareholders And A Lead Plaintiff Deadline Of June 19, 2018

The Klein Law Firm Announces A Class Action Commenced On Behalf Of Myriad Genetics, Inc. Shareholders And A Lead Plaintiff Deadline Of June 19, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Myriad Genetics, Inc.

MYGN INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Myriad Genetics, Inc. And A Lead Plaintiff Deadline Of June 19, 2018

MYGN INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Myriad Genetics, Inc. And A Lead Plaintiff Deadline Of June 19, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Myriad Genetics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 19, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Myriad Genetics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 19, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Myriad Genetics, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of purchasers of Myriad Genetics, Inc.

TheStreet Quant Rating: B (Buy)